Jim Hoyes

Jim HoyesJim Hoyes is a proven, effective leader with strong commercial results and broad biopharmaceutical experience across multiple therapeutic areas and specialty spaces.

Prior to joining Alitair as our CEO, Jim has had a long and successful career in the pharmaceutical industry. He founded and led the consulting firm RxC to a global presence and consulted with many leading pharmaceutical companies including:  J&J and Novartis.

Prior founding RxC Jim was President and Head of US operations at EMD Serono, Inc. from 2011 to 2013. As President of EMD Serono, he developed and executed the Merck KGaA business plans for the US Market. He had full P/L responsibility for the US commercial business and grew the business from $600M in sales to $2 billion in sales. Jim averaged double-digit growth at EMD Serono in his tenure.

His areas of direct responsibility include Medical, Regulatory and BD; indirect responsibility for US activities of Global Research & Development based in Billerica, MA as Managing Director of US. During his tenure as President, Jim built and developed a high performing Executive Leadership Team. He also served as the key member of the Merck Serono Global Operations Committee.

Jim successfully executed General Manager and Managing Director responsibilities. He was also responsible for operations in Rockland MA, Billerica MA and Washington DC.

Jim was also responsible for implementing the US portion of Merck’s “Fit for 2018” program to improve profitability. He also successfully implemented a Corporate Integrity Agreement; Chief Compliance Officer was a direct report. As lead US executive, he served as Merck’s representative on industry trade groups (PhRMA, BIO) and with government officials in MA and Washington, DC.

Jim Hoyes has a long track record of creating strategies and driving exceptional performance in the life sciences sector. In addition to providing advisory services to clients, Jim focuses on corporate development initiatives in the life sciences sector and the implementation of key strategic initiatives designed to scale up the firm’s global operations. Jim has deep expertise in all areas of corporate development and commercialization of pharmaceutical and biotechnology products. He has led a number of financial transactions including licensing and M&A deals.

Jim is on the board of MassBIO and has served on the boards of PhRMA and BIO. Jim is also involved with the boards of several non-profit community service organizations in the greater Boston area.  Jim received a B.S. in Biology from Penn State University


William W. Howard, Ph.D., MBA
President & Chairman

William HowardDr. William W. Howard has twenty-five years of pharmaceutical experience ranging from laboratory research, to the roll out of sales forces in Europe, to the development of new FDA approved products.  Howard has worked to develop new products in many categories of prescription and OTC drugs including COPD, Cough, Smoking Cessation, Cholesterol Reduction, Anti-Ulcer, Anti-Arthritic and Migraine therapy.  
He began his pharmaceutical career with research on drugs of abuse.  Following a stint of teaching at Dartmouth College and a post-doctoral at Northwestern, he entered the pharmaceutical industry with the Miles Labs division of Bayer and then moved to Parke-Davis as head of Marketing Management Science. He left Parke-Davis to found Ellard Inc., a pharmaceutical marketing software company and later, after selling Ellard, he founded SDM Inc., a highly successful global consulting firm. Dr. Howard became involved with Adams in 2001 when the first approval letter for Mucinex® was received and he was asked to help with the unexpected OTC status of the product.  He continued as a consultant for Adams until 2004 when he joined the company and later became Senior Vice President of New Products and Business Development.  

As Sr. VP, he managed all new product development initiatives and all corporate M&A, business development and licensing activity for the company. In addition, he was responsible for managing the development of new intellectual property on a global basis.  Dr. Howard was a member of the Business Operations Team (BOT) and was the key driver of the development of the strategic plan employed by Adams. He played a critical role in the initial contact with Reckitt-Benckiser.

William Howard received a Bachelor's and Master's degree from Cleveland State University and a Ph.D. in Experimental Psychology and Statistics from the University of New Mexico.  He did post-doctoral work in epidemiology at the Center for Health Services at Northwestern University where he did research on infant mortality.  He holds an MBA from Frederick Taylor University.


Peter Wolfe
Chief Financial Officer

Peter WolfeMr. Wolfe has spent his career in various financial roles in the financial services, specialty finance and the pharmaceutical/healthcare industries.  Most recently Mr. Wolfe has spent his time cultivating start-up organizations in various healthcare entities, often dealing with complicated business models to develop a financial framework for success for many of these first of their kind businesses.  Mr. Wolfe has spent the last 14 years of his career in the healthcare industry with half of that time spent at Kos Pharmaceuticals, a publicly traded, fully-integrated specialty pharmaceutical company.  Mr. Wolfe assisted in guiding Kos to 27 straight quarters of meeting or exceeding Wall Street quarterly earnings estimates.  Finding the most cost-effective way to run a business through the design of more efficient systems is the hallmark of his career achievements.  Mr. Wolfe has his BBA from the University of Miami  and his MBA from the University of Pittsburgh.

Helmut H. Albrecht, MD, MS, FFPM
Chief Scientific Officer



Dr. Helmut H. Albrecht is Chief Scientific Officer at Alitair. He is a 25+ year veteran of the pharmaceutical business and brings a wealth of product development experience to Alitair.  Most recently, Helmut was head of R&D at Adams Respiratory Therapeutics (Adams) where he managed a wide variety of product innovation as well as clinical and other development projects for various respiratory conditions (esp. in cough, COPD and allergy). He was also a member of the senior management team at Adams.

Prior to joining Adams, Helmut was VP of global Preclinical and Clinical Development and Drug Safety for the Novartis Consumer Health (NCH) OTC business unit and before the globalization of the NCH R&D organization, he served as VP for R&D OTC, North America with responsibility for all R&D functions in the NCH OTC business unit in NA. Earlier in his career he held key positions in the area of pharmaceutical medicine, involving Rx and OTC drugs as well as dietary supplements at SmithKline Beecham Consumer Health, Procter & Gamble OTC Health Care and P&G Pharmaceuticals, and Altana Pharmaceuticals.

Helmut has a doctor of medicine from the University of Heidelberg as well as a Master of Science degree in Management & Policy and an advanced New York State Certificate in Health Care Management from SUNY at Stony Brook.  He has a diploma in pharmaceutical medicine and is a fellow, as well as previous board member, of the Faculty of Pharmaceutical Medicine (FFPM). 

Allen Langjahr
General Counsel

Allen LangjahrAllen Langjahr serves as General Counsel for Alitair. Mr. Langjahr brings more than 27 years of experience as a corporate and healthcare lawyer to his role at Alitair. Mr. Langjahr served as in-house General Counsel to two PBMs, pharmacies, and a specialty insurance company providing prescription drug benefit coverage. Representative clients include Fortune 500 companies, Part D PDP applicants and plans, PBMs, pharmaceutical companies, health information technology and chain, mail order, and specialty pharmacies. Mr.Langjahr's corporate and healthcare experience includes advice and counsel on strategic planning, regulatory compliance, healthcare transactions, intellectual property matters, due diligence/acquisitions, start-up financing, and general corporate matters. Mr.Langjahr graduated with a Bachelor's degree in Accounting from Walsh College University and a Juris Doctorate from Vanderbilt University School of Law. Mr.Langjahr is admitted to practice law in California and New Jersey. He is a member of the American Health Lawyers Association, the Academy of Managed Care Pharmacy and the National Council for Prescription Drug Programs.

Russell F. Somma, Ph.D.
Research and Development

Russ SommaRuss Somma is an industry veteran with over 30 years of product development experience, primarily at Ciba-Geigy / Novartis.  While at Novartis he held a series of positions in early  and late stage product development as well as process introduction  which culminated in his position as Technical Project Leader responsible for several novel oral solid dosage forms.  He is currently  President of SommaTech, LLC a consulting firm focused on helping clients meet the manufacturing and quality control requirements for FDA new product approvals.  He has  assisted several clients in overcoming FDA Consent Decrees that required total cessation of all manufacturing operations. With Dr. Somma’s help, several have resumed full production operations.
Over the span of his career, Dr. Somma has been involved with every phase of product development from bench top formulations and pilot scale manufacturing to the establishment of full commercial scale operations.  Multi-particulate systems are a particular expertise for Somma.
He has been involved in the development, approval and PAI of over 25 NDAs so has considerable experience working with the FDA.  Indeed, he received a “Special Recognition Award” from Janet Woodcock, MD of FDA for his work in developing the SUPAC-IR Equipment Guidance.  Further, he was awarded the “Hammer” by then VP Al Gore for his efforts to reduce red tape and help improve through put at FDA in the area of manufacturing equipment similarities and process technology.
Dr. Somma has more than 30 publications and presentations in the area of development, manufacturing and quality by design.  He is Past Chairman of the International Society of Pharmaceutical Engineers (ISPE) Product Quality Lifecycle Implementation (PQLI) Committee.
He received his BS, MS and Ph.D. in Pharmaceutical Science from Rutgers University.  He is a registered pharmacist, as well.


Frank  L. Koos
Vice President, Business Development

Frank KoosFrank Koos serves as Vice President of Business Development at Alitair. He is a sales, marketing, and business development leader with over 20 years of experience in the pharmaceutical industry.  Koos has a proven track record driving growth at start-up and leading global companies.

Koos has held multiple executive leadership roles throughout his career including Senior Vice President of Sales, Marketing, and Business Development for MiddleBrook Pharmaceuticals, which launched the first FDA-approved once-daily amoxicillin.  

Koos also served as the Vice President of Professional Sales at Adams Respiratory Therapeutics and continued in that role after global consumer goods powerhouse Reckitt Benckiser acquired Adams. Prior to Adams, Koos held successive leadership roles including Vice President of Sales for PharMetrics and Group Director, Sales and Service at IMS Health. Previously, Koos was a sales representative and a sales trainer for the Ortho Pharmaceutical division of Johnson and Johnson, and he served as a lieutenant in the United States Army. Koos graduated from Lehigh University with a Bachelor of Arts degree.

Faith Pomeroy-Ward
Senior Vice President, Corporate Development

Faith Pomeroy-WardFaith Pomeroy-Ward has over a decade of corporate communications, marketing, and business development experience in the pharmaceutical industry, and she is a prize-winning writer.  She has worked on many high-profile brands including Mucinex®, Delsym®, Verizon®, Moxatag®, Cepacol®, BiDil®, Eylea® and Twinings®.

Ms. Pomeroy-Ward began her pharmaceutical career in 2004 with a role in the marketing department at Adams Respiratory Therapeutics, the maker of Mucinex®.  In 2005, she was promoted to the investor relations/corporate communications function. When Adams was acquired by Reckitt Benckiser in 2008, she joined Verizon Telecom in its public affairs department.  Ms. Pomeroy-Ward was then recruited to lead the investor relations and corporate communications function at MiddleBrook Pharmaceuticals. In that role, she managed all aspects of the company's corporate communications and investor relations programs.  She also held key responsibilities in business development and marketing. In 2010, Ms. Pomeroy-Ward began providing corporate communications, investor relations, and marketing consulting services.  In 2011, she joined Alitair Pharmaceuticals as Vice President, Corporate Development.